Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Exploring Treatment-Driven Subclonal Evolution of Prognostic and Predictive Triple Biomarkers: Dual Gene Fusions and Chimeric RNA Variants in Subtypes of Acute Myeloid Leukemia Patients with KMT2A Rearrangement

Blood (2024) 144 (Supplement 1): 6099.

https://doi.org/10.1182/blood-2024-204217

Published: 2024

Journal Articles

Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2023-185481

Published: 2023

Journal Articles

Detection of Cryptic Gene Fusion and Chimeric RNA Variants in Relapsed/Refractory Acute Myeloid Leukemia Patients Diagnosed with KMT2A/Afdn Chromosomal Translocation

Blood (2023) 142 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2023-184951

Published: 2023

Journal Articles

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Blood (2023) 141 (11): 1265–1276.

https://doi.org/10.1182/blood.2022016362

Published: 2023

Includes: Supplemental data

Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4349–4351.

https://doi.org/10.1182/blood-2022-166609

Published: 2022

Journal Articles

A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

Bhagirathbhai Dholaria, Admasu Mamuye, Diana Yurewicz, Kristina Dabovic, Amy Yuet, Rafat Abonour, Kevin R. Kelly, Timothy J. Voorhees, Dickran Kazandjian

Blood (2022) 140 (Supplement 1): 12621–12622.

https://doi.org/10.1182/blood-2022-168960

Published: 2022

Journal Articles

Pathway Analysis Provides Mechanistic Insights into Navtemadlin (KRT-232) Activity and Synergy with Decitabine in Acute Myeloid Leukemia Preclinical Models

Jin Wang, Venu Valmeekam, Kaijin Wu, Jiang F. Zhong, Andres Stucky, Xuelian (Lili) Chen, Alex Duong, Jude Canon, Cecile Marie Krejsa, Kevin R. Kelly

Blood (2021) 138 (Supplement 1): 2232.

https://doi.org/10.1182/blood-2021-145364

Published: 2021

Journal Articles

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín Garcia-Gutiérrez, Henrik Hjorth-Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gerald Luscan, Andrea Viqueira, Frank Giles, Andreas Hochhaus

Blood (2021) 138 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2021-150352

Published: 2021

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

Blood (2019) 134 (Supplement_1): 229.

https://doi.org/10.1182/blood-2019-123711

Published: 2019

Journal Articles

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Blood (2019) 134 (Supplement_1): 1281.

https://doi.org/10.1182/blood-2019-129196

Published: 2019

Journal Articles

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 211.

https://doi.org/10.1182/blood-2018-99-116411

Published: 2018

Journal Articles

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Petronella J Lugtenburg, MD PhD, Kevin R. Kelly, MD PhD, Anas Younes, MD, Robert Gharavi, PharmD, David P. Tuck, MD, Stefan Klaus Barta, MD MRCP, MS

Blood (2018) 132 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2018-99-112527

Published: 2018

Journal Articles

Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities

Sikander Ailawadhi, Alvaro J. Alencar, MD, Madiha Iqbal, MBBS, Prachi Jani, MD, Salman Ahmed, MD, Aditya Mehta, Ruqin Chen, MD, Leyla Bojanini, MD, Moises Harari Turquie, MD, Kevin R Kelly, MD PhD, Prakash Vishnu, MD, Vivek Roy, MD, Anshika Singh, Abuzar Asif, Shishir David, Imran Siddiqi, MD PhD, Asher A. Chanan-Khan, MD, Taimur Sher, MD

Blood (2018) 132 (Supplement 1): 4867.

https://doi.org/10.1182/blood-2018-99-119494

Published: 2018

Journal Articles

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Naval Daver, MD, Daniel A. Pollyea, MD, Karen W.L. Yee, MD, Pierre Fenaux, MD PhD, Joseph M. Brandwein, MD FRCPC, Norbert Vey, Giovanni Martinelli, Kevin R Kelly, MD PhD, Gail J. Roboz, MD, Jacqueline S. Garcia, Arnaud Pigneux, MD PhD, Smita Kshirsagar, Monique Dail, Jue Wang, Mehrdad Mobasher, Lin-Chi Chen, Wan-Jen Hong, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 813.

https://doi.org/10.1182/blood.V130.Suppl_1.813.813

Published: 2017

Journal Articles

Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics

Tania Jain, MD, Rafael Fonseca, MD, Ruqin Chen, MD, Raj Patel, MD, Prachi Jani, MD, Veronica Gonzalez De La Calle, MD, Zahara Meghji, James E. Hoffman, MD, Alvaro J. Alencar, MD, Kevin R Kelly, MD PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2017) 130 (Supplement 1): 864.

https://doi.org/10.1182/blood.V130.Suppl_1.864.864

Published: 2017

Journal Articles

Activation of Autophagy in Models of SF3B1 Mutant MDS

Blood (2017) 130 (Supplement 1): 4230.

https://doi.org/10.1182/blood.V130.Suppl_1.4230.4230

Published: 2017

Journal Articles

The Presence of Philadelphia Chromosome Does Not Confer Poor Prognosis in Adult Pre-B Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era - a Surveillance, Epidemiology, and End Results Database Analysis

Igwe John Igwe, Dongyun Yang, PhD, Merchant Akil, Noah Merin, George Yaghmour, Kevin R Kelly, MD PhD, Giridharan Ramsingh, MD

Blood (2017) 130 (Supplement 1): 2567.

https://doi.org/10.1182/blood.V130.Suppl_1.2567.2567

Published: 2017

Journal Articles

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

Kevin R Kelly, MD PhD, Claudia M Espitia, Weiguo Zhao, Kaijin Wu, Valeria Visconte, PhD, Faiz Anwer, MD, Christine M Calton, PhD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2017) 130 (Supplement 1): 3137.

https://doi.org/10.1182/blood.V130.Suppl_1.3137.3137

Published: 2017

Journal Articles

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Kevin R. Kelly, MD PhD, Claudia M. Espitia, Weiguo Zhao, Valeria Visconte, PhD, Matt Coffey, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 3960.

https://doi.org/10.1182/blood.V128.22.3960.3960

Published: 2016

NARROW

Exploring Treatment-Driven Subclonal Evolution of Prognostic and Predictive Triple Biomarkers: Dual Gene Fusions and Chimeric RNA Variants in Subtypes of Acute Myeloid Leukemia Patients with KMT2A Rearrangement

Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia

Detection of Cryptic Gene Fusion and Chimeric RNA Variants in Relapsed/Refractory Acute Myeloid Leukemia Patients Diagnosed with KMT2A/Afdn Chromosomal Translocation

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma

Pathway Analysis Provides Mechanistic Insights into Navtemadlin (KRT-232) Activity and Synergy with Decitabine in Acute Myeloid Leukemia Preclinical Models

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics

Activation of Autophagy in Models of SF3B1 Mutant MDS

The Presence of Philadelphia Chromosome Does Not Confer Poor Prognosis in Adult Pre-B Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era - a Surveillance, Epidemiology, and End Results Database Analysis

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only